Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViraCyte announces positive phase 2 trial results
The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1. Viralym-M is an "off-the-shelf", 3rd party T-cell product
The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1. Viralym-M is an "off-the-shelf", 3rd party T-cell product
Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and
This marks the second program Ovid has advanced into Phase 2 clinical development this year. Takeda and Ovid formed a global collaboration focused on the clinical development and
Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking,
Ligand is also entitled to future milestones and royalties from this antibody. WuXi Biologics was previously contracted by its Chinese partner Harbin Gloria Pharmaceuticals to discover and develop
The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. “Takeda’s extensive knowledge and expertise in
The study will examine the effectiveness of PLX-R18 as a treatment for Acute Radiation Syndrome (ARS) prior to, and within the first 24 hours of exposure to radiation.
The financing was co-led by new investor Wellington Management Company LLP and by a large US-based, healthcare-focused fund, participating as an existing Atreca investor. Additional participation included new
This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation. Evotec paid a total consideration of
In November 2016, the FDA granted ADCETRIS Breakthrough Therapy Designation (BTD) for the treatment of patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma who